The objective of the University of Chicago Breast Cancer SPORE Developmental Research Program (DRP) is to create a streamlined and transparent mechanism for soliciting and selecting exciting and novel research projects that have significant potential for translational success. Such projects may be collaborative among scientists within our SPORE, or have collaborations outside the SPORE environment, but must be innovative, potentially high impact, and preferably multi-disciplinary. This program will be led by Dr. Geoffrey Greene, a leader in the estrogen receptor field with a strong interest in translating basic science to clinical breast cancer, and Dr. Suzanne Conzen, a physician-scientist and medical oncologist specializing in breast cancer whose laboratory uses large scale genomic approaches to identify novel anti-apoptotic signaling pathways contributing to the transformation of breast epithelial cells. Specifically, the SPORE DRP will 1) establish a mechanism for soliciting DRP applications that reaches beyond cancer center members and the local SPORE community to all biological, physical, computer and social science faculty members at the University of Chicago and Argonne National Laboratory, as well as to investigators at other SPOREs nationwide;2) encourage, support, and nurture interdisciplinary collaboration using the expertise of our interdisciplinary Internal Scientific Advisory Committee;3) select and assess projects that help generate new hypotheses for development as full-fledged SPORE projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA125183-04
Application #
7884643
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
4
Fiscal Year
2009
Total Cost
$98,701
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Guindalini, Rodrigo Santa; Zheng, Yonglan; Abe, Hiroyuki et al. (2018) Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clin Cancer Res :
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Zheng, Yonglan; Walsh, Tom; Gulsuner, Suleyman et al. (2018) Inherited Breast Cancer in Nigerian Women. J Clin Oncol 36:2820-2825
Wang, Shengfeng; Ogundiran, Temidayo; Ademola, Adeyinka et al. (2018) Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev 27:636-643
Debiasi, Márcio; Polanczyk, Carisi A; Ziegelmann, Patrícia et al. (2018) Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol 8:156
Geeleher, Paul; Huang, R Stephanie (2017) Exploring the Link between the Germline and Somatic Genome in Cancer. Cancer Discov 7:354-355
Hon, Jason; Hwang, Michelle S; Charnetzki, Meara A et al. (2017) Kinetic characterization of the inhibition of protein tyrosine phosphatase-1B by Vanadyl (VO2+) chelates. J Biol Inorg Chem 22:1267-1279
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778
Johnston, Henry Richard; Hu, Yi-Juan; Gao, Jingjing et al. (2017) Identifying tagging SNPs for African specific genetic variation from the African Diaspora Genome. Sci Rep 7:46398
Nath, Aritro; Wang, Jacqueline; Stephanie Huang, R (2017) Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia. Mol Diagn Ther 21:621-631

Showing the most recent 10 out of 203 publications